WHWK

Peers: PYXS MGNX STRO CTMX VRXA IMNM ZYME BOLT CMPX ANL

| Held by: IWM VTI VXF IWN VTWO IWC OASC AVSC GSSC VTWV

Index	RUT
Market Cap	180.15M
Enterprise Value	-9.83M
Income	-79.83M
Sales	0.00M
Book/sh	3.21
Cash/sh	3.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	23
IPO	Aug 08, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.98
P/C	0.95
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	17.38
Current Ratio	17.38
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.11
EPS next Y	-0.87
EPS next Q	-0.21
EPS this Y	-179.22%
EPS next Y	5.43%
EPS next 5Y	-
EPS past 3/5Y	50.16% 58.28%
Sales past 3/5Y	-22.27% -13.29%
EPS Y/Y TTM	-1813.57%
Sales Y/Y TTM	-100.00%
EPS Q/Q	73.63%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	32.36% 100.00%

Insider Own	42.36%
Insider Trans	0.00%
Inst Own	57.85%
Inst Trans	10.98%
ROA	-42.60%
ROE	-44.98%
ROIC	-43.64%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.53%
SMA50	-21.02%
SMA200	-17.35%
Trades

Shs Outstand	57.01M
Shs Float	32.86M
Short Float	8.25%
Short Ratio	7.39
Short Interest	2.71M
52W High	5.49 -42.49%
52W Low	1.97 60.41%
Volatility	6.80% 5.51%
ATR (14)	0.20
RSI (14)	37.31
Beta	0.98
Rel Volume	0.34
Avg Volume	366.76K
Volume	38,277

Perf Week	9.34%
Perf Month	-18.13%
Perf Quarter	-14.59%
Perf Half Y	-21.59%
Perf YTD	30.58%
Perf Year	28.98%
Perf 3Y	-19.80%
Perf 5Y	-88.34%
Perf 10Y	-
Recom	1.57
Target Price	7.33
Prev Close	3.25
Price	3.16
Change %	-2.77%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-26	Initiated	Stifel	Buy	$9
Jul-13-26	Initiated	Leerink Partners	Outperform	$9
Jun-25-26	Initiated	B. Riley Securities	Buy	$10
Feb-05-26	Initiated	Oppenheimer	Outperform	$6
Aug-27-24	Downgrade	Piper Sandler	Overweight → Neutral	$5 → $1.75
Aug-21-24	Downgrade	TD Cowen	Buy → Hold
Aug-21-24	Downgrade	Jefferies	Buy → Hold	$11 → $1.50
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-11-22	Initiated	Jefferies	Buy	$45
Oct-01-21	Initiated	Cowen	Outperform
Sep-14-21	Initiated	Ladenburg Thalmann	Buy	$51
Sep-08-21	Initiated	Piper Sandler	Overweight	$45

Show Previous Ratings

Oct-01-26 08:00AM	Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 (PR Newswire)
Sep-13-26 09:30PM	Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 (PR Newswire)
Sep-10-26 04:05PM	Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors (PR Newswire)
Sep-02-26 08:00AM	Whitehawk Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-06-26 08:00AM	Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights (PR Newswire) +15.48%
08:00AM	Loading…
Jul-07-26 08:00AM	Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development (Business Wire)
May-30-26 02:30PM	Whitehawk Therapeutics Presents Real-World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 (PR Newswire)
May-28-26 04:05PM	Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference (PR Newswire)
May-21-26 08:38PM	WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise (Stocktwits)
05:05PM	Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload (PR Newswire)
May-20-26 08:00AM	Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit (PR Newswire)
May-15-26 08:00AM	Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum (PR Newswire) -7.84%
May-13-26 08:00AM	Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing (PR Newswire) +25.77%
May-07-26 08:00AM	Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights (PR Newswire) -5.06%
Apr-19-26 06:00PM	Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026 (PR Newswire)
04:05PM	Loading…
Apr-16-26 04:05PM	Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series (PR Newswire) +8.46%
Apr-10-26 07:00AM	Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 (PR Newswire)
Mar-17-26 04:30PM	Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 (PR Newswire)
Mar-12-26 08:00AM	Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights (PR Newswire)
Mar-03-26 01:30PM	Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027 (MarketBeat)
Feb-26-26 08:00AM	Whitehawk Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-25-26 02:21PM	Aadi Bioscience Conference: CEO Spotlights Whitehawk ADC Pipeline, Cash Runway Through 2028 (MarketBeat) +5.77%
Feb-18-26 09:41AM	Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy? (Zacks)
08:00AM	Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (PR Newswire)
Feb-13-26 09:33AM	Should You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release? (Zacks) -5.32%
Jan-08-26 08:00AM	Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 (PR Newswire)
Dec-01-25 08:00AM	Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer (PR Newswire)
Nov-26-25 08:00AM	Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (PR Newswire) +6.98%
Nov-11-25 08:00AM	Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London (PR Newswire)
Nov-06-25 08:00AM	Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (PR Newswire) -6.67%
12:30PM	Loading…
Oct-24-25 12:30PM	Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC (PR Newswire)
Oct-17-25 09:45AM	Tempus AI Fuels Growth Through Strategic Biotech Collaborations (Zacks) -15.33%
Oct-16-25 08:30AM	Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research (Business Wire) +24.29%
Sep-02-25 08:00AM	Whitehawk Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-12-25 05:32AM	US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche (GlobeNewswire)
Aug-07-25 08:00AM	Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
Jul-22-25 08:00AM	Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference (PR Newswire)
Jun-19-25 08:00AM	Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series (PR Newswire)
Jun-13-25 08:44AM	Implied Volatility Surging for Whitehawk Therapeutics Stock Options (Zacks)
May-28-25 08:00AM	Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference (PR Newswire)
May-21-25 08:00AM	Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit (PR Newswire)
May-08-25 04:05PM	Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
Mar-26-25 08:00AM	Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals (PR Newswire)
Mar-19-25 11:52AM	Whitehawk Therapeutics Inc. (WHWK) Q4 2024 Earnings Call Transcript (SeekingAlpha)
Mar-14-25 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update (PR Newswire)
Mar-04-25 04:05PM	Aadi Bioscience Announces Closing of $100 Million PIPE Financing (PR Newswire)
Mar-03-25 08:00AM	Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders (PR Newswire) -10.16%
Feb-24-25 08:00AM	Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference (PR Newswire)
Feb-18-25 08:00AM	Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer (PR Newswire)
Feb-05-25 04:05PM	Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025 (PR Newswire) +6.23%
Dec-21-24 06:31AM	Aadi Biosciences Strategic Agreements and Funding Moves (TipRanks)
Dec-19-24 06:30PM	Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO and $100 Million PIPE Financing (PR Newswire) +46.12%
Nov-06-24 08:00AM	Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update (PR Newswire) +6.53%
Oct-30-24 04:05PM	Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update (PR Newswire)
Aug-20-24 05:00PM	Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates (PR Newswire)
Aug-07-24 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update (PR Newswire)
Jul-31-24 04:05PM	Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update (PR Newswire)
Jul-05-24 01:07PM	3 Russell 2000 Stocks to Sell in July Before They Crash & Burn (InvestorPlace)
May-29-24 04:05PM	Aadi Bioscience to Participate in the Jefferies Healthcare Conference (PR Newswire) -6.38%
May-23-24 05:30PM	Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire) -5.70%
May-09-24 01:52PM	Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 12:53PM	AADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -12.80%
08:00AM	Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update (PR Newswire)
May-01-24 08:01AM	Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update (PR Newswire)
Apr-09-24 08:00AM	Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Apr-03-24 09:40AM	Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-18-24 09:40AM	Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-17-24 08:00AM	Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) (PR Newswire)
Mar-15-24 10:43AM	Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.85%
Mar-13-24 09:05AM	Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +11.34%
08:00AM	Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update (PR Newswire)
Mar-06-24 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update (PR Newswire)
Mar-05-24 04:30PM	Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PR Newswire) -13.35%
Mar-01-24 04:08PM	Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO for the Treatment of Malignant PEComa (PR Newswire) +26.82%
Feb-26-24 04:05PM	Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference (PR Newswire)
Jan-26-24 04:05PM	Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (PR Newswire)
Jan-19-24 04:05PM	Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium (PR Newswire)
Dec-15-23 09:14AM	Why Is Aadi Bioscience (AADI) Stock Down 56% Today? (InvestorPlace) -56.42%
Dec-14-23 04:05PM	Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations (PR Newswire)
Nov-08-23 08:46AM	Aadi Bioscience Q3 Loss Per Share Narrows (RTT News)
08:00AM	Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update (PR Newswire)
Nov-06-23 04:05PM	Aadi Bioscience to Participate in Jefferies London Healthcare Conference (PR Newswire)
Nov-01-23 04:05PM	Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update (PR Newswire) +6.48%
Oct-19-23 04:05PM	Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting (PR Newswire)
Oct-12-23 04:05PM	Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Oct-05-23 04:05PM	Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium (PR Newswire)
Oct-03-23 04:05PM	Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) (PR Newswire) -6.51%
Oct-02-23 08:00AM	Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer (PR Newswire) -11.16%
Sep-20-23 04:30PM	Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-05-23 08:00AM	Aadi Bioscience to Participate at Upcoming Investor Conferences (PR Newswire) -6.31%
Aug-09-23 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update (PR Newswire) -6.85%
Aug-02-23 08:00AM	Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update (PR Newswire)
May-25-23 05:30PM	Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
May-23-23 08:00AM	Aadi Bioscience to Participate in Upcoming Investor Events (PR Newswire)
May-10-23 08:00AM	Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial (PR Newswire) -16.61%
May-03-23 08:00AM	Aadi Bioscience to Report First Quarter 2023 Results and Operational Update (PR Newswire)
Apr-26-23 04:05PM	Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-14-23 01:00PM	Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Apr-06-23 04:30PM	Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 (PR Newswire)
Mar-28-23 08:00AM	Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update (PR Newswire) -5.52%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Giacobello Scott M.	CHIEF FINANCIAL OFFICER	Apr 16 '26	Sale	4.13	141,600	584,808	295,224	Apr 17 04:53 PM
Giacobello Scott M.	CHIEF FINANCIAL OFFICER	Apr 15 '26	Sale	3.86	77,000	297,220	436,824	Apr 17 04:53 PM
Giacobello Scott M.	Officer	Apr 15 '26	Proposed Sale	3.85	233,766	899,999		Apr 15 08:03 PM
BALL BRYAN	See remarks	Apr 14 '26	Sale	3.64	92,460	336,554	397,106	Apr 15 07:59 PM
BALL BRYAN	See remarks	Apr 13 '26	Sale	3.46	26,389	91,306	489,566	Apr 15 07:59 PM
BALL BRYAN	See remarks	Apr 09 '26	Sale	3.57	50,000	178,500	522,551	Apr 13 08:34 PM
BALL BRYAN	See remarks	Apr 10 '26	Sale	3.43	6,596	22,624	515,955	Apr 13 08:34 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Apr 09 '26	Sale	3.38	14,500	49,010	518,622	Apr 10 06:46 PM
BALL BRYAN	Officer	Apr 09 '26	Proposed Sale	3.30	196,969	649,998		Apr 09 08:38 PM
Lennon David James	Officer	Apr 09 '26	Proposed Sale	3.38	4,364	14,750		Apr 09 07:54 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Apr 06 '26	Sale	3.51	102,395	359,406	691,154	Apr 08 08:32 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Apr 07 '26	Sale	3.43	94,087	322,718	597,067	Apr 08 08:32 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Apr 08 '26	Sale	3.40	63,945	217,413	533,122	Apr 08 08:32 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Apr 02 '26	Sale	3.48	26,858	93,466	793,549	Apr 03 06:17 PM
Lennon David James	Officer	Apr 02 '26	Proposed Sale	3.48	297,421	1,034,399		Apr 02 09:35 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Mar 02 '26	Sale	3.31	5,100	16,879	44,579	Mar 10 07:36 PM
Giacobello Scott M.	CHIEF FINANCIAL OFFICER	Mar 02 '26	Sale	3.31	2,594	8,585	28,100	Mar 10 07:36 PM
BALL BRYAN	See remarks	Mar 02 '26	Sale	3.31	1,834	6,070	206,019	Mar 10 07:35 PM

Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Morristown, NJ.

PresidentDr. David J. Lennon Ph.D.

Founder & DirectorDr. Neil P. Desai Ph.D.

CFOMr. Scott M. Giacobello CPA

Chief Technical Operations OfficerMr. Bryan Ball

Chief Scientific OfficerDr. David Dornan Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Whitehawk Therapeutics Inc

Upgrade your Finviz experience